News & Events
Tucson, AZ, February 5th 2024, SynCardia Systems, LLC., a Picard Medical Company, proudly announces that the U.S. Patent and Trademark Oﬃce (USPTO) has allowed claims of its groundbreaking patent application “Next Generation Total Artificial Heart” covering next generation total artificial heart designs. Read More >
Team at Baylor University Medical Center Dallas TX recently implanted and bridged a young woman to heart transplantation. Read More >
On the heels of the FDA approval of the new software updates for the Freedom Driver, SynCardia was out in force at the 2023 Annual Conference of the American Society of Artificial Internal Organs (ASAIO). Read More >
A preliminary proxy statement has been filed with the Securities and Exchange Commission by Altitude Acquisition Corp. for its proposed merger with Picard Medical, Inc and SynCardia Systems LLC. Read More >
As a platinum sponsor of the HeartHackathon, Tucson, Arizona-based SynCardia is demonstrating its commitment to education, innovation, and to advancing the field of artificial heart technologies. Read More >
SynCardia Systems, LLC., a Picard Medical Company, today announced that the U.S. Food and Drug Administration (FDA) has approved an update of the SynCardia TAH label with real world data further confirming the safety and performance of the Companion 2 Driver. Read More >
Celebrating Randy’s incredible 10-year anniversary since receiving a Total Artificial Heart! Despite facing immense challenges, Randy has shown us what it means to live life to the fullest and embrace every opportunity with unwavering determination. Read More >
We are excited about the announcement that Patrick NJ Schnegelsberg is the new Chief Executive Officer of SynCardia Systems, LLC the parent company of Picard Medical, Inc. A global leader in mechanical heart replacement technology. Read More >
The SynCardia team eagerly walked the 5 km course, aiming to raise awareness and funds for heart disease while fostering a sense of community. Read More >
Close On The Heels Of The Recent FDA Approval Of The Software Upgrades To The Freedom Driver, Team SynCardia Was Out In Force At The Annual Conference Of International Society For Heart And Lung Transplantation (ISHLT). Read More >
SynCardia Manufactures and Distributes the First-and-Only Commercially Available and FDA Approved Total Artificial Heart. SynCardia is Entering a Rapid Growth Phase Supported by New Product Development, Label Expansion, and International Growth. Read More >
SynCardia Systems LLC is pleased to announce that the US Food and Drug Administration (FDA) has approved significant software upgrades to the Freedom Portable Driver. Read More >
1992 E. Silverlake Rd. Tucson, AZ 85713
+1 520-545-1234 | firstname.lastname@example.org
The SynCardia Total Artificial Heart is a treatment option for cardiac transplant-eligible patients at risk of imminent death from biventricular failure.
Medical Advice Disclaimer
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE
The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or a qualified health care provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information you have read on this website.
© SynCardia Systems, LLC | All rights reserved.